Literature DB >> 29974077

Aberrant expression of ETS1 and ETS2 proteins in cancer.

Elizabeth A Fry1, Kazushi Inoue1.   

Abstract

The ETS transcription factors regulate expression of genes involved in normal cell development, proliferation, differentiation, angiogenesis, and apoptosis, consisting of 28 family members in humans. Dysregulation of these transcription factors facilitates cell proliferation in cancers, and several members participate in invasion and metastasis by activating gene transcription. ETS1 and ETS2 are the founding members of the ETS family and regulate transcription by binding to ETS sequences. They are both involved in oncogenesis and tumor suppression depending on the biological situations used. The essential roles of ETS proteins in human telomere maintenance have been suggested, which have been linked to creation of new Ets binding sites. Recently, preferential binding of ETS2 to gain-of-function mutant p53 and ETS1 to wild type p53 (WTp53) has been suggested, raising the tumor promoting role for the former and tumor suppressive role for the latter. The oncogenic and tumor suppressive functions of ETS1 and 2 proteins have been discussed.

Entities:  

Keywords:  ETS1; ETS2; cancer; expression; mutant p53; telomerase

Year:  2018        PMID: 29974077      PMCID: PMC6027756          DOI: 10.15761/CRR.1000151

Source DB:  PubMed          Journal:  Cancer Rep Rev        ISSN: 2513-9290


  179 in total

1.  Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP.

Authors:  Mary L Nelson; Hyun-Seo Kang; Gregory M Lee; Adam G Blaszczak; Desmond K W Lau; Lawrence P McIntosh; Barbara J Graves
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-13       Impact factor: 11.205

2.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Authors:  Peter C Hollenhorst; Mary W Ferris; Megan A Hull; Heejoon Chae; Sun Kim; Barbara J Graves
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

Review 3.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

4.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

5.  Chromosomal localization of the human proto-oncogene c-ets.

Authors:  C de Taisne; A Gegonne; D Stehelin; A Bernheim; R Berger
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

Review 6.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

Review 7.  Telomeres-structure, function, and regulation.

Authors:  Weisi Lu; Yi Zhang; Dan Liu; Zhou Songyang; Ma Wan
Journal:  Exp Cell Res       Date:  2012-09-21       Impact factor: 3.905

8.  Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer.

Authors:  Sinan Zhu; Ryan T Mott; Elizabeth A Fry; Pankaj Taneja; George Kulik; Guangchao Sui; Kazushi Inoue
Journal:  Am J Pathol       Date:  2013-08-11       Impact factor: 4.307

Review 9.  ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).

Authors:  David Adler; Nicolas Wernert
Journal:  Int J Oncol       Date:  2012-02-21       Impact factor: 5.650

10.  Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways.

Authors:  R T Sitaram; S Degerman; B Ljungberg; E Andersson; Y Oji; H Sugiyama; G Roos; A Li
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

View more
  9 in total

1.  PBX1, EMCN and ERG are associated with the sub-clusters and the prognosis of VHL mutant clear cell renal cell carcinoma.

Authors:  Haiwei Wang; Xinrui Wang; Liangpu Xu; Ji Zhang
Journal:  Sci Rep       Date:  2022-05-27       Impact factor: 4.996

2.  ETS1 Suppresses Tumorigenesis of Human Breast Cancer via Trans-Activation of Canonical Tumor Suppressor Genes.

Authors:  Gi-Cheon Kim; Choong-Gu Lee; Ravi Verma; Dipayan Rudra; Taemook Kim; Keunsoo Kang; Jong Hee Nam; Young Kim; Sin-Hyeog Im; Ho-Keun Kwon
Journal:  Front Oncol       Date:  2020-05-14       Impact factor: 6.244

3.  MicroRNA-146b Overexpression Promotes Human Bladder Cancer Invasion via Enhancing ETS2-Mediated mmp2 mRNA Transcription.

Authors:  Junlan Zhu; Chunxia Xu; Liming Ruan; Jianping Wu; Yang Li; Xingguo Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-14       Impact factor: 8.886

4.  Erinacine C Activates Transcription from a Consensus ETS DNA Binding Site in Astrocytic Cells in Addition to NGF Induction.

Authors:  Monique Rascher; Kathrin Wittstein; Barbara Winter; Zeljka Rupcic; Alexandra Wolf-Asseburg; Marc Stadler; Reinhard W Köster
Journal:  Biomolecules       Date:  2020-10-14

Review 5.  Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma.

Authors:  Enakshi Sivasudhan; Neil Blake; Zhi-Liang Lu; Jia Meng; Rong Rong
Journal:  Front Cell Dev Biol       Date:  2021-04-01

Review 6.  CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals.

Authors:  Alina Catalina Palcau; Valeria Canu; Sara Donzelli; Sabrina Strano; Claudio Pulito; Giovanni Blandino
Journal:  Mol Cancer       Date:  2022-01-28       Impact factor: 27.401

7.  Study on the role of transcription factor SPI1 in the development of glioma.

Authors:  Baoshun Du; Wuji Gao; Yu Qin; Jiateng Zhong; Zheying Zhang
Journal:  Chin Neurosurg J       Date:  2022-04-01

8.  Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma.

Authors:  Kanchan Vishnoi; Rong Ke; Navin Viswakarma; Piush Srivastava; Sandeep Kumar; Subhasis Das; Sunil Kumar Singh; Daniel R Principe; Ajay Rana; Basabi Rana
Journal:  Cell Death Dis       Date:  2022-07-04       Impact factor: 9.685

9.  Factor VIII as a potential player in cancer pathophysiology.

Authors:  Gillian E Walker; Simone Merlin; Diego Zanolini; Andrea Vandoni; Alessandro Volpe; Gianluca Gaidano; Guido Valente; Martina Olivero; Antonia Follenzi
Journal:  J Thromb Haemost       Date:  2022-01-11       Impact factor: 16.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.